Contraindicationsfor COVID-19 vaccination currently include: 1. Those who are allergic to theactive ingredient of the vaccine, any inactive ingredient, substances used inthe manufacturing process, or those who have developed allergies from previoussimilar vaccines; 2. Patients who have had severe allergicreactions to vaccines in the past (such as acute allergic reactions, angoneeuroticedema, dyspnea, etc.); 3, suffering from uncontrolled epilepsy andother serious neurological diseases (such as transverse myelitis,Guillain-Barre syndrome, demyelinating diseases, etc.); 4. Those who are febrile, or suffering fromacute diseases, or acute episodes of chronic diseases, or patients withuncontrolled serious chronic diseases; 5. Pregnant women. Tips Refer to the Novel Coronavirus VaccineTechnical Guide published by the NHC. For those who are contraindicated orshould be used with caution as listed in the manual, please refer to thevaccination recommendations for specific groups as follows. Persons aged 60 and over are at high risk ofsevere illness or death after infection with novel Coronavirus. At present, only a limited number of the fourconditionally approved Phase iii clinical trials of novel Coronavirus vaccineshave been included in this population, and there are no data on the vaccine'sprotective efficacy in this population. However, the data from phase ⅰ / ⅱ clinical study showed that the vaccinesafety in this population was good. Compared with the population aged 18-59,the titer of neutralizing antibody was slightly lower after vaccination, butthe positive conversion rate of neutralizing antibody was similar, suggesting thatthe vaccine can also have a certain protective effect on the population agedover 60, so vaccination is recommended. 2. There is no clinical trial data for thevaccines currently available for people under 18 years of age, and vaccinationis not recommended for people under 18 years of age. Chronic disease group Chronic disease groupis the group with high risk of severe illness and death after infection ofnovel Coronavirus. Patients with chronic diseases with stablehealth conditions and good drug control are not contraindicated for novelCoronavirus vaccine and are recommended to be vaccinated. 4. Based on the understanding of the safetyof the vaccines, special medical measures (e.g. termination of pregnancy) fornovel Coronavirus vaccine alone are not recommended for women of childbearingage and lactating age who are pregnant after vaccination or who have beenvaccinated with the vaccine for an unknown pregnancy. Pregnancy examination andfollow-up are recommended. For women planning pregnancy, the novelCoronavirus vaccine alone need not delay pregnancy. Although there are currently no clinical dataon the effect of novel Coronavirus vaccine in lactating women on infants andyoung children, based on the understanding of vaccine safety, it is recommendedto vaccinate lactating women (e.g., medical personnel, etc.) who are at highrisk of Novel Coronavirus infection. In view of the importance of breastfeedingfor the nutrition and health of infants and young children, it is recommendedto continue breastfeeding after the novel Coronavirus vaccine has beenadministered to lactating women in line with international practice. Immunocompromised persons Immunocompromisedpersons are at high risk of severe illness and death after infection with novelCoronavirus. There are currently no data on the safety and efficacy ofnovel coronavirus vaccines in this population (e.g., patients with malignantneoplasms, nephrotic syndrome, HIV), human immunodeficiency virus (HIV). The immune response and protective effect ofthe vaccine may be reduced. For inactivated vaccines and recombinantsubunit vaccines, vaccination is recommended according to the safetycharacteristics of previous vaccines of the same type. For adenovirus vector vaccine, although thevector virus used is replication-deficient, there is no previous safety data ofthe same type of vaccine. It is recommended that individuals be vaccinatedafter being fully informed that the benefits outweigh the risks. 6. Existing research data from previous COVID-19 patients or infected persons indicate that re-infection within 6 months ofNovel coronavirus infection is rare. Prior COVID-19 virus infection (patient orasymptomatic) can be given one dose after 6 months on the basis of fullnotification. Currently, people aged 18 and above may experience pain,tenderness, redness and itching at the injection site within 24 hours aftervaccination, and in most cases, it will disappear spontaneously within 2-3days. After vaccination, transient fever and fatigue may occur,which disappear spontaneously in a short time without treatment. In addition, all vaccinators should read theinformed consent carefully before inoculation. If they feel unwell, they canpostpone inoculation.
https://www.teamstandmedical.com/